Global Information
회사소개 | 문의 | 비교리스트

ACE-536(Luspatercept) : 의약품 인사이트와 시장 예측(2030년)

ACE-536 (Luspatercept) - Drug Insight and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 09월 상품 코드 959694
페이지 정보 영문 50 Pages
가격
US $ 2,750 ₩ 3,231,000 PDF (Single User License)
US $ 5,500 ₩ 6,463,000 PDF (Site License)
US $ 8,250 ₩ 9,695,000 PDF (Global License)


ACE-536(Luspatercept) : 의약품 인사이트와 시장 예측(2030년) ACE-536 (Luspatercept) - Drug Insight and Market Forecast - 2030
발행일 : 2020년 09월 페이지 정보 : 영문 50 Pages

Luspatercept는 베타지중해빈혈 및 골수이형성증후군의 빈혈 치료제입니다. 이것은 Celgene와 공동으로 Acceleron Pharma에 의해 개발되었습니다. Luspatercept-aamt는 다수의 내인성 전환성장인자 베타(TGF-B) 상과 리간드에 결합하는 재조합 융합 단백질로, Smad2/3 신호전달을 줄입니다. 이 약물은 후기 적혈구 성숙 또는 적혈구 분화를 촉진하는 퍼스트 클래스 적혈구 성숙제(EMA)입니다. 미국식품의약국은 2013년에 희귀의약품 지정을, 2015년에 패스트 트랙(우선승인심사제도) 지정을 부여했습니다.

ACE-536(Luspatercept)에 대해 다루었으며, 미국, 유럽 5개국(독일, 프랑스, 이탈리아, 스페인, 영국) 및 일본 7개 주요 시장의 ACE-536(Luspatercept) 상세(제품 상세, 작용기서, 투여량, 합성 경로, 약리학적 연구, 규제 마일스톤, 기타 개발 활동 등)을 제공합니다.

목차

제1장 제품 개요

  • 적응증
  • 작용기서
  • 투약과 관리
    • 제형과 강점
  • 합성 경로
  • 약리학
    • 약력학
    • 약물동태
  • 유해 반응
  • 제품 현황
  • ACE-536(Luspatercept) 개발 마일스톤
  • 출시 상세
    • 미국
    • 유럽
    • 일본
  • 특허 상세

제2장 SWOT 분석

  • 애널리스트의 견해

제3장 규제 마일스톤

  • 승인
  • 연구개발
  • 임상시험 정보
  • 안전성과 유효성
  • 제품 개발 활동

제4장 시장 평가

  • 주요 7개국 시장 분석
  • 미국
  • 유럽
  • 일본
  • 주요 조사 결과

제5장 시장 경쟁사

제6장 새로운 치료

제7장 부록

  • 보고서 구입 옵션
KSM 20.09.16

List of Tables

  • Table 1 ACE-536 (Luspatercept), Description
  • Table 2 ACE-536 (Luspatercept), Trial Diversification
  • Table 3 ACE-536 (Luspatercept), Marketed Details United States
  • Table 4 ACE-536 (Luspatercept), Marketed Details Europe
  • Table 5 ACE-536 (Luspatercept), Marketed Details Japan
  • Table 6 Patent Details: ACE-536 (Luspatercept)
  • Table 7 ACE-536 (Luspatercept), Clinical Trial Description, 2020
  • Table 8 Safety and Efficacy Results for ACE-536 (Luspatercept)
  • Table 9 ACE-536 (Luspatercept), 7MM Market Size from 2017 to 2030 (in Million USD)
  • Table 10 ACE-536 (Luspatercept), US Market Size from 2017 to 2030 (in Million USD)
  • Table 11 ACE-536 (Luspatercept), EU Market Size from 2017 to 2030 (in Million USD)
  • Table 12 ACE-536 (Luspatercept), EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Table 13 ACE-536 (Luspatercept), Japan Market Size from 2017 to 2030 (in Million USD)
  • Table 14 Market Competitors
  • Table 15 Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of ACE-536 (Luspatercept)
  • Figure 2 Patent Details, ACE-536 (Luspatercept)
  • Figure 3 ACE-536 (Luspatercept), 7MM Market Size from 2017 to 2030 (in Million USD)
  • Figure 4 ACE-536 (Luspatercept), US Market Size from 2017 to 2030 (in Millions USD)
  • Figure 5 ACE-536 (Luspatercept), EU Market Size from 2017 to 2030 (in Millions USD)
  • Figure 6 ACE-536 (Luspatercept), EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Figure 7 ACE-536 (Luspatercept), Japan Market Size from 2017 to 2030 (in Millions USD)

"ACE-536 (Luspatercept)- Drug Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the ACE-536 (Luspatercept) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Drug Summary:

Luspatercept is a drug for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. It was developed by Acceleron Pharma in collaboration with Celgene. Luspatercept-aamt is a recombinant fusion protein that binds multiple endogenous Transforming growth factor-beta (TGF-B) superfamily ligands, reducing Smad2 / 3 signalling. The drug is a first-in-class erythroid maturation agent (EMA) that promotes late-stage erythroid maturation or differentiation of red blood cells. The U.S. Food and Drug Administration awarded orphan drug status in 2013 and fast track designation in 2015 for both indications.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around ACE-536 (Luspatercept).
  • The report contains historical and forecasted sales for ACE-536 (Luspatercept) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of ACE-536 (Luspatercept).

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ACE-536 (Luspatercept) Analytical Perspective by DelveInsight

  • In-depth ACE-536 (Luspatercept) Market Assessment

This report provides a detailed market assessment of ACE-536 (Luspatercept) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

  • ACE-536 (Luspatercept) Clinical Assessment

The report provides the clinical trials information of ACE-536 (Luspatercept) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for ACE-536 (Luspatercept) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence ACE-536 (Luspatercept) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to ACE-536 (Luspatercept) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of ACE-536 (Luspatercept).
  • Our in-depth analysis of the sales data of ACE-536 (Luspatercept) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ACE-536 (Luspatercept) in the market.

Key Questions:

  • What is the prescribed dosage and strengths of ACE-536 (Luspatercept) are available in the market?
  • What are the common adverse reactions or side effects of ACE-536 (Luspatercept)?
  • What is the product type, route of administration and mechanism of action of ACE-536 (Luspatercept)?
  • What are the chemical specifications of ACE-536 (Luspatercept)?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of ACE-536 (Luspatercept), and what is its future?
  • What are the marketed details of ACE-536 (Luspatercept) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to ACE-536 (Luspatercept) and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of ACE-536 (Luspatercept)?
  • In which countries ACE-536 (Luspatercept) got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for ACE-536 (Luspatercept)?
  • How the safety and efficacy results determined the approval of ACE-536 (Luspatercept)?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ACE-536 (Luspatercept) development?
  • What are the key designations that have been granted to ACE-536 (Luspatercept)?
  • What is the historical and forecasted market scenario of ACE-536 (Luspatercept)?
  • How is the market trend of ACE-536 (Luspatercept) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to ACE-536 (Luspatercept)?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Table of Contents

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of ACE-536 (Luspatercept)
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

  • 7.1. Report Purchase Options
Back to Top
전화 문의
F A Q